New Endometriosis Pill Approved
This is a England news story, published by BBC, that relates primarily to NHS news.
England news
For more England news, you can click here:
more England newswomen's health news
For more women's health news, you can click here:
more women's health newsBBC news
For more news from BBC, you can click here:
more news from BBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like women's health news, you might also like this article about
New endometriosis pill. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest charity Endometriosis UK news, endometriosis news, women's health news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Endometriosis UKBBC
•Health
Health
New endometriosis pill approved on NHS in England

72% Informative
First daily pill for treating endometriosis symptoms has been approved for use on the NHS in England .
The relugolix combination therapy pill works by blocking specific hormones that contribute to the condition.
It will only be available on NHS for people who have already tried all other treatments and found they did not help - equivalent to 1,000 women a year.
Charity says pill gives patients more choice but will help only a relatively small number of people.
VR Score
64
Informative language
55
Neutral language
85
Article tone
informal
Language
English
Language complexity
48
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
1
Affiliate links
no affiliate links